Samyang Holdings Biopharmaceuticals Division’s

PCL Filler “Lafullen” Proven for Safety and Efficacy

May.13, 2022

- Research results on Lafullen’s safety and efficacy posted on SCI-level international academic journal after 24-month-long research

- Greater safety, immediate volume improvement, and long-term volume retention confirmed in comparison to conventional PCL fillers

- Development of safe and effective Lafullen procedural protocols in progress with specialists based on research results

Long-term safety and efficacy of Lafullen, a new filler brand of Samyang Holdings, have been proven by research results. Dermal fillers are injected to alleviate wrinkles and improve volume with ingredients that are safe to the human body under the subcutaneous layer.

Samyang Holdings Biopharmaceuticals Division (Head: Lee Young-Joon) announced on May 11 that a research paper that details the safety of its polycaprolactone (PCL)-based filler Lafullen and the efficacy of alleviating nasolabial folds has been published on the international academic journal Dermatologic Therapy. Dermatologic Therapy is a Science Citation Index (SCI)-level international journal that provides the latest research data and results in the field of dermatology. 

Dr. Kim Beom-joon of Chung-Ang University Hospital's Department of Dermatology conducted a comparative study between Lafullen and conventional PCL fillers on 59 Korean men and women to prove Lafullen's safety. Dr. Kim also measured its efficacy of alleviating nasolabial folds with global standard indices to verify not only an immediate volume improvement but also safe and stable volume retention effect at each of the major points in early, middle and later phases.

Considering the nature of PCL fillers, which are generally retained for over two years, Samyang Holdings Biopharmaceuticals Division has conducted an additional observation research after the completion of the initial one-year research and successfully secured data on its long-term safety and efficacy. Moreover, development of a procedural protocol is to be carried out together with medical professionals based on the quantitative data secured through this research in relation to the alleviation of nasolabial folds, including Wrinkle Severity Rating Scale (WSRS) data, Global Aesthetic Improvement Scale (GAIS) data, and volume changes utilizing 3D scanners.

Lafullen is a cosmetic surgery filler, which began to be developed by Samyang Holdings Biopharmaceuticals Division in 2015 and acquired an approval from the Ministry of Food and Drug Safety in 2021. The main component of Lafullen is PCL, a biodegradable and macromolecule medical substance to which the patented technology of Samyang Holdings Biopharmaceuticals Division is applied and, thus, users can expect a reduced feeling of irritation and a more natural volume than conventional PCL fillers.

An official from Samyang Holdings Biopharmaceuticals Division said, “A variety of aspects including volume retention, safety and stability have been proven by research data. Based on these research results, we will develop procedural protocols with which safe and highly satisfactory procedural outcomes can be obtained, and it will be provided to medical personnel both in Korea and overseas.”